The Need for Risk Factor Assessment in Atherothrombotic Vascular Disease

ABSTRACT

Risk factors for cardiovascular disease are characteristically associated with an increased likelihood of disease. Prospective studies of incident disease are less prone to bias than cross-sectional or case-control studies of prevalent disease. Meta-analyses of prospective studies provide more reliable estimates of the strength of association of risk factors with risk of disease than individual studies. Meta-analyses of intervention studies provide the most reliable estimates of reversibility of disease risk through prolonged reduction of classical risk factors (e.g., blood pressure, serum cholesterol). Emerging potential risk factors include markers of infection, inflammation, and thrombosis; their possible roles in causation and in risk prediction require much further study.

KEYWORDS

Coronary heart disease - stroke - risk factors - epidemiology - meta-analyses

REFERENCES

• 1 Kannel W B, Dawber T R, Jagen A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease-six year follow-up experience: the Framingham Study.  Ann Intern Med . 1961;  55 332-40
• 2 Kannel W B. Contributions of the Framingham Study to the conquest of coronary artery disease.  Am J Cardiol . 1988;  62 1109-1112
• 3 PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack.  Lancet . 2001;  358 1033-1041
• 4 Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial.  Lancet . 2002;  360 7-22
• 5 MacMahon S, Peto R, Cutler J. Blood pressure, stroke, and coronary heart disease. 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.  Lancet . 1990;  335 765-774
• 6 Collins R, Peto R, MacMahon S. Blood pressure, stroke, and coronary heart disease. 2. short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.  Lancet . 1990;  335 827-838
• 7 Prospective Studies Collaboration (in press). Lancet 2002
• 8 Wood D, de Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention.  Eur Heart J . 1998;  19 1434-1503
• 9 Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R. on behalf of the British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, and British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice.  Heart . 1999;  S1-S29
• 10 Scottish Intercollegiate Guidelines Network (SIGN). Lipids and the primary prevention of coronary heart disease. A national clinical guideline (SIGN 40) Edinburgh: SIGN 1999
• 11 Sanmuganathan P S, Ghahramani P, Jackson P R, Wallis E J, Ramsay L E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.  Heart . 2001;  85 265-271
• 12 Libby P. Molecular basis of the acute coronary syndromes.  Circulation . 1995;  91 2844-2850
• 13 Davies M J. Stability and instability: two faces of coronary atherosclerosis.  Circulation . 1996;  94 2013-2020
• 14 Ross R. Atherosclerosis-an inflammatory disease.  N Eng J Med . 1999;  340 115-126
• 15 Ridker P M, Cushman M, Stampfer M J, Tracy R P, Hennekens C H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.  N Engl J Med . 1997;  336 973-979
• 16 Ridker P M, Rifai N, Clearfield M. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.  N Engl J Med . 2001;  344 1959-1965